CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $348,194
- in 1 filing
Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-03 | Harmon Seth Chief Financial Officer | Option exercise | +6,267 | 9,881 | ||
| 2026-03-03 | Harmon Seth Chief Financial Officer | Shares withheld for taxes | −2,091 | $29.32 | $61K | 7,790 |
| 2026-03-03 | Harmon Seth Chief Financial Officer | Option exercise · Restricted Stock Units | −6,267 | 18,801 | ||
| 2026-03-03 | Beetham Thomas W. Chief Operating Officer | Option exercise | +9,409 | 16,409 | ||
| 2026-03-03 | Beetham Thomas W. Chief Operating Officer | Shares withheld for taxes | −3,138 | $29.32 | $92K | 13,271 |
| 2026-03-03 | Beetham Thomas W. Chief Operating Officer | Option exercise · Restricted Stock Units | −9,409 | 28,227 | ||
| 2026-03-03 | Mahoney Stephen F. President and CEO | Option exercise | +18,357 | 40,757 | ||
| 2026-03-03 | Mahoney Stephen F. President and CEO | Shares withheld for taxes | −7,627 | $29.32 | $224K | 33,130 |
| 2026-03-03 | Mahoney Stephen F. President and CEO | Option exercise · Restricted Stock Units | −18,357 | 55,071 | ||
| 2026-03-02 | Tousignant Jennifer Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +119,300 | 119,300 | ||
| 2026-03-02 | Tousignant Jennifer Chief Legal Officer | Grant or award · Restricted Stock Units | +23,850 | 23,850 | ||
| 2026-03-02 | Harmon Seth Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +102,850 | 102,850 | ||
| 2026-03-02 | Harmon Seth Chief Financial Officer | Grant or award · Restricted Stock Units | +20,550 | 20,550 | ||
| 2026-03-02 | Beetham Thomas W. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +176,550 | 176,550 | ||
| 2026-03-02 | Beetham Thomas W. Chief Operating Officer | Grant or award · Restricted Stock Units | +35,300 | 35,300 | ||
| 2026-03-02 | Mahoney Stephen F. President and CEO | Grant or award · Stock Option (Right to Buy) | +559,600 | 559,600 | ||
| 2026-03-02 | Mahoney Stephen F. President and CEO | Grant or award · Restricted Stock Units | +111,900 | 111,900 | ||
| 2026-03-02 | Tripuraneni Radhika Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +95,800 | 95,800 | ||
| 2026-03-02 | Tripuraneni Radhika Chief Medical Officer | Grant or award · Restricted Stock Units | +19,150 | 19,150 | ||
| 2025-12-31 | Tousignant Jennifer Chief Legal Officer | Sale | −2,272 | $31.16 | $71K | 0 |
Page 2 of 10 · 182 trades